Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ALLP's course correction leads to a surprise

Confronted with a hitch that will add three to six months to the timeline for its NDA for LiquiVent, Alliance Pharmaceutical Corp. suspended enrollment of its Phase III trial in pediatric patients with acute respiratory distress syndrome (ARDS). Trial monitors noted a precipitous drop in mortality of control patients four months after

Read the full 526 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers